^
    4d
    COCOON: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (clinicaltrials.gov)
    P2, N=305, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) • minocycline
    9d
    Effects of minocycline on acrylamide-induced neurotoxicity in Wistar rats. (PubMed, Iran J Basic Med Sci)
    Furthermore, intraperitoneal injection of minocycline (40 mg/kg) with ACR reduced the levels of MDA, IL-1β, and caspase-3-cleaved proteins in the cerebral cortex. Administration of minocycline exhibits both prophylactic and therapeutic properties against ACR-induced neurotoxicity primarily through anti-oxidant, anti-apoptotic, and anti-inflammatory properties.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta)
    |
    minocycline
    9d
    Differential Modulation of JAK/STAT3 Signaling and BCL-2 Family Proteins by Tetracycline Analogues in Leukemia Models. (PubMed, Pharmaceutics)
    This study aimed to investigate the anticancer potential of three tetracycline analogues chemically modified tetracycline-3 (COL-3), doxycycline (DOX), and minocycline (MIN) in leukemia models, with a particular focus on their cytotoxic effects and modulation of the JAK2/STAT3 signaling pathway. Among them, COL-3 emerges as the most potent analogue and acts through both JAK/STAT-dependent and -independent mechanisms. This work supports further investigation of COL-3 as a candidate for drug repurposing strategies in hematological malignancies.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • ANXA5 (Annexin A5)
    |
    minocycline
    14d
    NSUN5 Deficiency Drives Anxiety-Like Behaviors in Mice via Increased Microglial Activation and Impaired LTD Induction in the Basolateral Amygdala. (PubMed, FASEB J)
    Furthermore, the anxiety-like behaviors in NSUN5-deficient mice were also relieved by rmFGF2 or minocycline treatments. Taken together, our study unveils a previously unknown effect of NSUN5 on anxiety disorders and a role of NSUN5 in regulating OPCs-microglia interaction and synaptic plasticity of BLA.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • FGF2 (Fibroblast Growth Factor 2) • IL1B (Interleukin 1, beta) • NSUN5 (NOP2/Sun RNA Methyltransferase 5)
    |
    minocycline
    19d
    MISTICH: Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage (clinicaltrials.gov)
    P3, N=1192, Recruiting, Beijing Tiantan Hospital | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> Apr 2026
    Enrollment open • Trial initiation date
    |
    minocycline
    20d
    Stony Brook Medicine Anti-Inflammatory Trial (clinicaltrials.gov)
    P4, N=42, Not yet recruiting, Stony Brook University | Trial completion date: Jan 2031 --> Jan 2032 | Trial primary completion date: Jun 2030 --> Jun 2031
    Trial completion date • Trial primary completion date
    |
    celecoxib oral • minocycline
    20d
    A randomized, open-access, single-dose, two-sequence, two-cycle, cross-bioequivalence trial of minocycline Hydrochloride Capsules (50mg) under fasting and postprandial administration conditions in healthy subjects in China (ChiCTR2600119848)
    P=N/A, N=52, Completed, The Fifth Affiliated Hospital of Guangzhou Medical University; The Fifth Affiliated Hospital of Guangzhou Medical University
    New trial
    |
    minocycline
    20d
    Efficacy and Safety of Different Dual Regimens Based on Tegoprazan for the Eradication of Helicobacter pylori Infection in Treatment-naïve Patients: A Prospective, Randomized, Open-label, Multicenter Trial (ChiCTR2600119367)
    P=N/A, N=624, Peking University Third Hospital; Peking University Third Hospital
    New trial
    |
    minocycline
    20d
    Effect of Kangfuxin Liquid combined with minocycline and ofloxacin on chronic periodontitis and periodontal inflammation (ChiCTR2600118944)
    P=N/A, N=100, Affiliated Hospital of Jiangsu University; Affiliated Hospital of Jiangsu University
    New trial
    |
    minocycline
    25d
    Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo. (PubMed, Adv Sci (Weinh))
    Here, we use photoactivatable multi-inhibitor liposomes (PMILs) as a clinically translatable strategy to immunomodulate and enhance PDAC treatment using FDA-approved agents: minocycline for tumor priming by downregulating Tdp1, benzoporphyrin derivative incorporated into the liposomal bilayer for photodynamic priming (PDP) of the microenvironment, and irinotecan (IRI) for cytotoxicity. This combination achieved sustained local tumor regression, abscopal effects in untreated distant tumors, and a significant improvement in long-term survival (63%). By integrating clinically approved agents with non-overlapping mechanisms within a light-activated delivery platform, this approach enhances IRI efficacy, reprograms the TME, and promotes antitumor immunity, offering a translatable strategy to sensitize PDAC to chemo- and immunotherapy.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)
    |
    irinotecan • minocycline
    29d
    EMPHASIS-2: Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis (clinicaltrials.gov)
    P3, N=934, Not yet recruiting, Beijing Tiantan Hospital
    New P3 trial
    |
    minocycline
    1m
    Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention (clinicaltrials.gov)
    P1, N=0, Withdrawn, Northwell Health | N=24 --> 0 | Trial completion date: Sep 2025 --> Mar 2026 | Recruiting --> Withdrawn
    Enrollment change • Trial completion date • Trial withdrawal
    |
    minocycline